The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.

Abstract:

OBJECTIVES:A germline BIM deletion polymorphism has been proposed to predict a poor treatment efficacy of certain kinase inhibitors. The current study aimed to explore whether the BIM deletion polymorphism predicts the treatment efficacy of sorafenib for advanced hepatocellular carcinoma (HCC). METHODS:All patients who were enrolled in clinical trials to receive sorafenib-containing regimens as first-line therapy for advanced HCC and consented to providing peripheral blood samples were included. Polymerase chain reaction followed by gel electrophoresis was used to detect the germline BIM deletion polymorphism. RESULTS:A total of 89 patients were enrolled; 69 (77%) patients had chronic hepatitis B infection, and 18 (20%) had chronic hepatitis C infection. The heterozygous BIM deletion polymorphism was identified in 9 (10%) patients. Patients with and without the BIM deletion polymorphism had similar response rates (11 vs. 6%) and disease control rates (56 vs. 61%). The time to progression, progression-free survival, and overall survival were similar between patients with and without the BIM deletion polymorphism. After adjusting for basic clinicopathologic variables and treatment regimens, the BIM polymorphism still could not predict treatment outcomes. CONCLUSIONS:The BIM deletion polymorphism was not associated with the treatment efficacy of sorafenib for advanced HCC.

journal_name

Oncology

journal_title

Oncology

authors

Shao YY,Chang YL,Huang CY,Hsu CH,Cheng AL

doi

10.1159/000356019

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

312-6

issue

5

eissn

0030-2414

issn

1423-0232

pii

000356019

journal_volume

85

pub_type

杂志文章

相关文献

ONCOLOGY文献大全
  • Potential applications of high-dose megestrol acetate in breast cancer.

    abstract::Empiric clinical trials have revealed new mechanisms by which hormonal therapies may exert their antitumor effects. Initial studies using escalated doses of agents like toremifene and megestrol acetate have yielded interesting results, showing responses in hormone-receptor-negative patients and in patients progressing...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000227121

    authors: Abrams JS,Gutheil J,Aisner J

    更新日期:1992-01-01 00:00:00

  • Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.

    abstract:BACKGROUND:Neoadjuvant chemotherapy (NAC) has become prevalent in esophageal squamous cell carcinoma (ESCC), but its long-term prognostic advantages remain unclear. The latest prognostic outcomes in clinical Stage (cStage) II/III ESCC with NAC were herein elucidated. PATIENTS AND METHODS:NAC prior to curative treatmen...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000455128

    authors: Yamashita K,Hosoda K,Moriya H,Katada C,Sugawara M,Mieno H,Komori S,Katada N,Watanabe M

    更新日期:2017-01-01 00:00:00

  • Local interleukin-2 therapy for cancer, and its effector induction mechanisms.

    abstract::This paper reviews the effectiveness of local interleukin-2 (IL-2) therapy and its effector induction mechanisms in vivo. Local therapy with IL-2 and/or lymphokine-activated killer (LAK) cells is associated with far fewer side effects than systemic treatment. Local infusions of IL-2 into malignant pleural effusions an...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000227331

    authors: Sone S,Ogura T

    更新日期:1994-03-01 00:00:00

  • Role of mammography, ultrasound and large core biopsy in the diagnostic evaluation of papillary breast lesions.

    abstract:BACKGROUND:It is well recognized that distinguishing benign from malignant papillary lesions of the breast may pose challenging diagnostic problems. To prospectively evaluate the potential role of mammography, ultrasound and image-guided core biopsy in the diagnosis of papillary lesions of the breast. METHODS:1,442 wo...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000074643

    authors: Puglisi F,Zuiani C,Bazzocchi M,Valent F,Aprile G,Pertoldi B,Minisini AM,Cedolini C,Londero V,Piga A,Di Loreto C

    更新日期:2003-01-01 00:00:00

  • Plasma diamine oxidase activity is a useful biomarker for evaluating gastrointestinal tract toxicities during chemotherapy with oral fluorouracil anti-cancer drugs in patients with gastric cancer.

    abstract:OBJECTIVES:Diamine oxidase (DAO) is an enzyme that catalyzes oxidation and is highly active in the mature upper villus cells of the intestinal mucosa. This study sought to evaluate plasma DAO activities during adjuvant chemotherapy in patients with gastric cancer. METHODS:We investigated 20 patients with gastric cance...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000336799

    authors: Namikawa T,Fukudome I,Kitagawa H,Okabayashi T,Kobayashi M,Hanazaki K

    更新日期:2012-01-01 00:00:00

  • Clonal composition of malignant fibrous histiocytoma: analysis by PCR-based assay of the human androgen receptor gene (HUMARA).

    abstract::Malignant fibrous histiocytoma (MFH), the most common soft-tissue sarcoma, consists mainly of two different cell populations: histiocytelike and fibroblastlike cells. It has been suggested to contain a large amount of reactive histiocytes and fibroblasts hard to distinguish from the tumor cells. In this study, the clo...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000011919

    authors: Fujita MQ,Hashida N,Shin M,Nakanishi H,Yoshihara W,Aozasa K

    更新日期:1998-11-01 00:00:00

  • The Ile646Val (2073A>G) polymorphism in the kinase-binding domain of A-kinase anchoring protein 10 and the risk of colorectal cancer.

    abstract:OBJECTIVE:The purpose of this study is to investigate whether the Ile646Val (2073A>G) polymorphism in the kinase-binding domain of A-kinase anchoring protein 10 (AKAP10) is related to the risk of colorectal cancer (CRC), clinicopathological variables and the environmental factors for the development of CRC. METHODS:Ap...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000201572

    authors: Wang MJ,Zhou ZG,Wang L,Yu YY,Zhang P,Zhang Y,Cui CF,Yang L,Li Y,Zhou B,Sun XF

    更新日期:2009-01-01 00:00:00

  • Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.

    abstract:PURPOSE:This phase I study (EudraCT No. 2006-001177-25) investigated aflibercept, a vascular endothelial growth factor decoy receptor protein (VEGF Trap), in combination with docetaxel, cisplatin, and 5-fluorouracil in patients with advanced solid tumors. PATIENTS AND METHODS:Patients received 2, 4, or 6 mg/kg of intr...

    journal_title:Oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1159/000440958

    authors: Bahleda R,Baker J,Massard C,Gadgeel SM,Rogers JE,Izzedine H,Deutsch E,Garris JL,Khan A,Boelle E,Assadourian S,Soria JC,Ajani JA

    更新日期:2016-01-01 00:00:00

  • HER-targeted tyrosine-kinase inhibitors.

    abstract::Improved understanding of tumor biology has led to the identification of numerous growth factors that are involved in malignant transformation and tumor progression. Many of these factors induce cellular responses through receptors with intrinsic tyrosine kinase (TK) activity. Therefore, inhibiting receptor TK activit...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000066198

    authors: Baselga J,Hammond LA

    更新日期:2002-01-01 00:00:00

  • Ondansetron: a cost-effective advance in anti-emetic therapy.

    abstract::A cost-effectiveness analysis is one form of full economic evaluation where drug acquisition costs and the costs that are incurred as a result of using a particular treatment are assessed together with clinical efficacy. This paper reviews two such studies. One of the studies was a prospective randomised cost-effectiv...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1159/000227175

    authors: Cox F,Hirsch J

    更新日期:1993-05-01 00:00:00

  • Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments.

    abstract:OBJECTIVE:New effective therapy is desirable for patients with non-small cell lung cancer (NSCLC) who have failed previous treatments. Fractionated administration of paclitaxel may be less toxic and more active against NSCLC. The aim of this study was to evaluate the activity and toxicity of weekly paclitaxel therapy f...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000079481

    authors: Yasuda K,Igishi T,Kawasaki Y,Kato K,Matsumoto S,Katayama S,Sako T,Shigeoka Y,Suyama H,Sugitani A,Yamamoto M,Hitsuda Y,Shimizu E

    更新日期:2004-01-01 00:00:00

  • Extrahepatic Hodgkin's disease with intrahepatic cholestasis: report of two cases.

    abstract::Liver is involved in about 5-8% of newly diagnosed Hodgkin's disease (HD) cases. The incidence reaches up to 50-60% in postmortem studies. In the literature only a few cases of idiopathic cholestatic jaundice have been described without an apparent cause and a paraneoplastic etiology has been suggested. We report 2 ca...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000012005

    authors: Yalçin S,Kars A,Sökmensüer C,Atahan L

    更新日期:1999-07-01 00:00:00

  • Elevation of Neutrophil-to-Lymphocyte Ratio before First-Line Chemotherapy Predicts a Poor Prognosis for Second-Line Chemotherapy in Gastric Cancer.

    abstract:OBJECTIVES:The neutrophil-to-lymphocyte ratio (NLR) has been proposed as an indicator of cancer-related inflammation. The aim of our study was to examine the prognostic value of the NLR for patients with advanced gastric cancer receiving second-line chemotherapy. METHODS:The association of overall survival (OS) in sec...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000493427

    authors: Inoue D,Sekiguchi S,Yamagata W,Maeda G,Yamada D,Fujiwara S,Itou S,Kurihara M,Hijioka Y,Shimoji K,Fujiki J,Nakazono A,Horike H,Yoshioka A,Ogura Y,Hatao F,Imamura K,Namiki S

    更新日期:2019-01-01 00:00:00

  • Prognostic value of syndecan-1 expression in breast cancer.

    abstract:OBJECTIVE:Syndecan-1 is a cell surface heparan sulphate proteoglycan which participates in cell proliferation, cell migration and cell-matrix interactions. Epithelial syndecan-1 expression is reduced in several malignant tumours, but in breast and pancreatic cancer, increased expression has also been described. Loss of...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000080280

    authors: Leivonen M,Lundin J,Nordling S,von Boguslawski K,Haglund C

    更新日期:2004-01-01 00:00:00

  • Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma.

    abstract::Twenty-two patients with metastatic breast carcinoma were treated with a combination of cisplatin (100 mg/m2 i.v. day 1) and etoposide (100 mg/m2 i.v. days 1-3). Eligible patients had measurable disease with normal organ functions, performance status < 3, age < 70 years and no previous chemotherapy for metastatic dise...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000227364

    authors: Lluch A,Azagra P,Cervantes A,Muñoz M,Alberola V,Santabarbara P,García-Conde J

    更新日期:1994-07-01 00:00:00

  • Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.

    abstract:OBJECTIVES:Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000487266

    authors: Vincenzi B,Badalamenti G,Armento G,Silletta M,Spalato Ceruso M,Catania G,Napolitano A,Maltese G,Valeri S,Incorvaia L,Santini D,Tonini G

    更新日期:2018-01-01 00:00:00

  • Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer.

    abstract:BACKGROUND AND OBJECTIVES:Even though the pathological background contributes to lymph node metastasis, the biological characteristics of tumors have also gained wide attention. In this study, the expression of the cadherin-catenin complex and p53 was studied in early gastric cancer. Their correlation with lymph node m...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000012020

    authors: Xiangming C,Hokita S,Natsugoe S,Tanabe G,Baba M,Takao S,Kuroshima K,Aikou T

    更新日期:1999-01-01 00:00:00

  • Polycythemia Vera Management and Challenges in the Community Health Setting.

    abstract::Patients with polycythemia vera (PV) experience shortened survival, increased risk of thromboembolic and hemorrhagic events, and burdensome symptoms. For all patients with PV, treatment with aspirin and hematocrit control with phlebotomy are recommended. In addition, patients with high-risk status or poor hematocrit c...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000454953

    authors: Gerds AT,Dao KH

    更新日期:2017-01-01 00:00:00

  • Effects of cycloheximide on chromatin-bound and -unbound PCNA in HeLa cells.

    abstract::We examined the effects of cycloheximide on the amount of chromatin-bound and -unbound PCNA subpopulations in HeLa cells. The chromatin-bound PCNA content decreased rapidly in the presence of cycloheximide, whereas the reduction of the total amount of PCNA was minimal even 24 h after the treatment with cycloheximide. ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227500

    authors: Sasaki K,Kurose A,Uesugi N,Kato A

    更新日期:1995-09-01 00:00:00

  • Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.

    abstract:BACKGROUND:Immuno-oncological (IO) therapies such as PD-1 and PD-L1 antibodies have been introduced in the treatment of advanced non-small cell lung cancer (NSCLC) since 2015 based on randomized trials showing unprecedented advantages in overall survival (OS) with hazard ratios (HRs) between 0.5 and 0.7. The impact of ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000500885

    authors: Faehling M,Kopp M,Schwenk B,Fallscheer S,Kramberg S,Eckert R

    更新日期:2019-01-01 00:00:00

  • Studies of actinomycin D induced B23-translocation in P388D1 cells implanted in DBA/2 mice.

    abstract::Nucleophosmin/B23 is a nucleolar phosphoprotein which redistributes from nucleoli to nucleoplasm (B23-translocation) when cells are exposed to certain anticancer drugs, particularly intercalators. The B23-translocation assay has been demonstrated in cell culture to correlate with drug effects and to detect drug-resist...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227043

    authors: Finch RA,Chan PK

    更新日期:1992-01-01 00:00:00

  • Serum alphafetoprotein in bladder carcinoma.

    abstract::112 cases, of varying ages, which were diagnosed as having carcinoma of the bladder by cystoscopy and biopsy from the tumor, were investigated for the presence of alphafetoprotein (AFP) in the sera. 59 (52.6%) out of the total, showed positive results, and no false positive results occured. Radioimmunoassay was capabl...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000225188

    authors: Alsabti EA

    更新日期:1977-01-01 00:00:00

  • Altered gene expression in rat colonic adenocarcinomas induced in an azoxymethane plus 2-amino-1-methyl-6-phenylimidazo[4,5-b]- pyridine initiation-promotion model.

    abstract::2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), the most abundant food-derived mutagenic/carcinogenic heterocyclic amine (HCA), has attracted particular attention as a probable human colon carcinogen. Some studies have shown that PhIP administered in the post-initiation phase is able to enhance rat colon carci...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000127423

    authors: Doi K,Hagihara A,Wei M,Yunoki T,Fukushima S,Wanibuchi H

    更新日期:2007-01-01 00:00:00

  • Sodium butyrate inhibits the enhancing effect of high fat diet on mammary tumorigenesis.

    abstract::We have studied the effect of butyrate on mammary tumorigenesis by 7,12-dimethylbenz(a)anthracene. As reported previously, a high incidence of mammary tumors was observed in rats fed a basal diet containing 20% margarine. However, the enhancing effect of margarine was inhibited when sodium butyrate was supplemented in...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227178

    authors: Yanagi S,Yamashita M,Imai S

    更新日期:1993-07-01 00:00:00

  • Matched-pair analysis in patients with advanced oropharyngeal cancer: surgery versus concurrent chemoradiotherapy.

    abstract:OBJECTIVE:The current study aimed to compare the therapeutic outcomes of surgery with those of chemoradiation for patients with advanced oropharyngeal cancer (OPC). METHODS:The data for 523 patients with previously untreated OPC were obtained from 12 institutions belonging to the Head and Neck Cancer Study Group in th...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000346908

    authors: Kano S,Homma A,Hayashi R,Kawabata K,Yoshino K,Iwae S,Hasegawa Y,Nibu K,Kato T,Shiga K,Matsuura K,Monden N,Fujii M

    更新日期:2013-01-01 00:00:00

  • Expression of platelet-activating factor receptor: a novel prognosticator in patients with hepatocellular carcinoma following hepatectomy.

    abstract:BACKGROUNDS AND AIMS:Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a phospholipid mediator and acts by binding to a specific G-protein-coupled receptor. Though various functions of PAF have been associated with tumor activities, the mechanism of PAF-PAF receptor signaling in the de...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000113149

    authors: Kitagawa D,Taketomi A,Kayashima H,Kuroda Y,Itoh S,Yamashita Y,Maehara Y

    更新日期:2007-01-01 00:00:00

  • Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis.

    abstract:BACKGROUND:Over the last few years only one large randomized phase III study has tried to prospectively assess the safety of cetuximab and panitumumab in a head-to-head comparison. Despite the similar overall toxicity profile, cetuximab and panitumumab retain peculiar safety characteristics that deserve to be deeply in...

    journal_title:Oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1159/000486338

    authors: Petrelli F,Ardito R,Ghidini A,Zaniboni A,Ghidini M,Barni S,Tomasello G

    更新日期:2018-01-01 00:00:00

  • Anal carcinoma: a clinical approach to p53 and RB gene proteins.

    abstract::The role of p53, retinoblastoma (RB) and c-erbB-2 gene proteins in the pathogenesis of anal carcinomas has been examined. A total of 97 patients were included in the study. c-erbB-2, RB and p53 proteins were abnormal in 0, 5 and 34% of the cases, respectively. No correlation was observed between p53 and age, sex, tumo...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227590

    authors: Tanum G,Holm R

    更新日期:1996-09-01 00:00:00

  • Chemoradiotherapy alone as the standard treatment of epidermoid esophageal carcinoma.

    abstract:OBJECTIVES:Surgery has traditionally been the treatment of choice for patients with potentially resectable esophageal carcinoma. Recently, however, definitive chemoradiotherapy (CRT) has been suggested as a preferred treatment modality. In this study, CRT results with or without surgery are compared. METHODS:A total o...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000333448

    authors: Salek R,Tabrizi FV,Bezenjani SE,Saedi HS,Ashkiki MH,Hosainzadeh SM,Mohtashami S

    更新日期:2011-01-01 00:00:00

  • Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.

    abstract:OBJECTIVES:Angiogenesis plays an important role in ovarian cancer. The interaction of platelet-derived growth factor receptor-beta (PDGFR-β) with vascular endothelial growth factor (VEGF) in the process of angiogenesis may represent an essential feature in the progression of the disease. METHODS:Patients with epitheli...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000351032

    authors: Mathey S,Graeser MK,Zu Eulenburg C,Woelber L,Trillsch F,Jaenicke F,Müller V,Milde-Langosch K,Mahner S

    更新日期:2013-01-01 00:00:00